Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,805
  • Shares Outstanding, K 35,520
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,450 K
  • 36-Month Beta 3.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.46

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.67 +7.19%
on 12/07/17
2.95 -39.32%
on 11/13/17
-0.47 (-20.80%)
since 11/10/17
3-Month
0.90 +98.89%
on 09/28/17
2.95 -39.32%
on 11/13/17
+0.72 (+67.29%)
since 09/11/17
52-Week
0.88 +103.41%
on 08/23/17
2.95 -39.32%
on 11/13/17
+0.35 (+24.31%)
since 12/09/16

Most Recent Stories

More News
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer....

ONCS : 1.74 (+2.30%)
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has added two patents to its broad patent portfolio....

ONCS : 1.74 (+2.30%)
OncoSec Receives $9.3 Million Warrant Exercise

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into entered into a Warrant Exercise Agreement...

ONCS : 1.74 (+2.30%)
Corporate News Blog - OncoSec Medical Reports Positive Updated Follow-Up Data from Phase-2 Trial of ImmunoPulse IL-12 in Combination with Pembrolizumab

Research Desk Line-up: Radius Health Post Earnings Coverage

RDUS : 32.00 (+1.27%)
ONCS : 1.74 (+2.30%)
2 Stocks That Should Be on Your Radar Now

CORAL GABLES, FL / ACCESSWIRE / November 9, 2017 / Lexington Biosciences, Inc. (LXGTF) is a medical device company that is focusing on measuring and monitoring the cardiovascular system. The company's...

LXGTF : 0.4745 (-0.57%)
ONCS : 1.74 (+2.30%)
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based cancer immunotherapies, will present emerging data from its novel, multi-gene expression platform termed Polycistronic...

ONCS : 1.74 (+2.30%)
OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients

OncoSec Medical Incorporated ("OncoSec" or "Company") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced positive updated long-term follow-up data from its...

ONCS : 1.74 (+2.30%)
OncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company

OncoSec Medical Incorporated ("OncoSec" or "Company") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Daniel J. O'Connor as CEO of...

ONCS : 1.74 (+2.30%)
Clinical Studies Elevating Biotech Drug Development to New Levels for Unmet Medical Needs

PALM BEACH, Florida, November 7, 2017 /PRNewswire/ --

CARA : 13.25 (-2.14%)
CTXR : 4.74 (-4.44%)
ONCS : 1.74 (+2.30%)
TXMD : 6.35 (+1.44%)
VBLT : 6.55 (-0.76%)
Clinical Studies Elevating Biotech Drug Development to New Levels for Unmet Medical Needs

Commitment to bring new drug developments to the market through highly regarded and respected clinical research and studies are of a continued result of ongoing collaborations with academic and medical...

CARA : 13.25 (-2.14%)
CTXR : 4.74 (-4.44%)
ONCS : 1.74 (+2.30%)
VBLT : 6.55 (-0.76%)
TXMD : 6.35 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 1.85
1st Resistance Point 1.80
Last Price 1.74
1st Support Level 1.70
2nd Support Level 1.65

See More

52-Week High 2.95
Fibonacci 61.8% 2.16
Fibonacci 50% 1.91
Last Price 1.74
Fibonacci 38.2% 1.67
52-Week Low 0.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.